Skip to content

Authored endpoint-conditioned ustekinumab amount and salvage reference

Authored endpoint-conditioned amount model with apparent distribution and fixed abstract protection/recycling; not a whole-body or pediatric physiology model.

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How do the reduced adult and pediatric presets distribute ustekinumab?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Initialized 390 mg conditional induction

Authored conditional amount model with specified apparent volumes, fixed transfer rates and an abstract drug-protection capacity. It is not an organ physiology or population simulation.

0–808.8 h

Scenario details

Initialized 390 mg conditional induction

Authored conditional amount model with specified apparent volumes, fixed transfer rates and an abstract drug-protection capacity. It is not an organ physiology or population simulation.

Readouts

Central concentration · mg/L
Conditional amount, flux, exposure or abstract-capacity quantity; not an independently validated biological endpoint.
Current drug amount · mg
Conditional amount, flux, exposure or abstract-capacity quantity; not an independently validated biological endpoint.
Accounted initial plus added amount · mg
Conditional amount, flux, exposure or abstract-capacity quantity; not an independently validated biological endpoint.
Mean central concentration · mg/L
Conditional amount, flux, exposure or abstract-capacity quantity; not an independently validated biological endpoint.
Occupied protection capacity fraction · dimensionless
Conditional amount, flux, exposure or abstract-capacity quantity; not an independently validated biological endpoint.

Study purpose

  • How do the model's key biological readouts change under initialized 390 mg conditional induction?

Assumptions

  • Endpoint conditioning and fixed authored inputs define this mathematical reference; no independent pediatric exposure prediction is assigned.
  • Five apparent amount pools do not represent 15 organs or four physiological spaces.
  • Abstract protected-drug capacity is inmg antibody equivalents, not measured receptor protein.
  • Initialized central amount is not a recovered clinical infusion; no source infusion duration or original patient trajectory is assigned.
  • No endogenous IgG competition, IL-12 p40 target, ontogeny, population variability, original project or clinical dose recommendation is represented.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
h
h
808.8 → 168

Time between reported samples.

h
20.22 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

Follow initialized antibody amount, later SC additions, apparent exchange and abstract salvage with explicit mg accounting.

Follow initialized antibody amount, later SC additions, apparent exchange and abstract salvage with explicit mg accounting.

Model details

12 parameters · 10 states · 10 equations · 28 derived outputs

Classification & API access
Therapeutic
Ustekinumab
Modality
Monoclonal antibody
Target
IL-12 / IL-23 p40
Disease / scope
Inflammatory bowel disease
ParameterDefaultUnitDescription
Linear elimination clearanceCL_linear_L_h0.005L/hFixed authored conditional coefficient; scenario-specific numeric values define each research case.
Systemic absorption fractionF_sc0.75fractionFixed authored conditional coefficient; scenario-specific numeric values define each research case.
Intercompartmental clearanceQ_L_h0.015L/hFixed authored conditional coefficient; scenario-specific numeric values define each research case.
Central distribution volumeVc_L3LFixed authored conditional coefficient; scenario-specific numeric values define each research case.
Peripheral distribution volumeVp_L2.4LFixed authored conditional coefficient; scenario-specific numeric values define each research case.
Abstract protected drug capacityfcrn_capacity_mg20mgFixed authored conditional coefficient; scenario-specific numeric values define each research case.
Abstract uptake pool catabolism ratek_endosomal_catabolism_h0.021/hFixed authored conditional coefficient; scenario-specific numeric values define each research case.
Central to uptake ratek_endosomal_uptake_h0.00021/hFixed authored conditional coefficient; scenario-specific numeric values define each research case.
Abstract protection ratek_fcrn_bind_h0.081/hFixed authored conditional coefficient; scenario-specific numeric values define each research case.
Protected drug recycling ratek_fcrn_recycle_h0.041/hFixed authored conditional coefficient; scenario-specific numeric values define each research case.
Protected drug release ratek_fcrn_unbind_h0.021/hFixed authored conditional coefficient; scenario-specific numeric values define each research case.
Nominal subcutaneous depot loss rateka_sc_h0.00251/hFixed authored conditional coefficient; scenario-specific numeric values define each research case.

Related models

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics